OPK · Opko Health, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OPK
this stock
Opko Health, Inc.
|
$1.20B | +27.8% | -14.9% | — | 4.8% |
|
TMO
Thermo Fisher Scientific Inc.
|
$251.20B | +17.2% | +14.5% | 36.6 | 1.5% |
|
DHR
Danaher Corp /De/
|
$157.77B | -2.0% | +8.5% | 39.8 | 1.3% |
|
NTRA
Natera, Inc.
|
$57.57B | +74.4% | -2.8% | — | 4.4% |
|
A
Agilent Technologies, Inc.
|
$48.56B | +24.9% | +6.4% | 33.9 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OPK | +16.7% | -4.7% | +33.1% | +0.0% | +27.8% |
| SPY | -1.5% | -0.9% | +7.7% | +0.5% | +12.4% |
| vs SPY | +18.2% | -3.8% | +25.4% | -0.5% | +15.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.